Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Adolor Corporation (NasdaqNM:ADLR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
620 Pennsylvania Avenue
Exton, PA 19341
Phone: (484) 595-1500
Fax: (484) 595-1515
Email: adolor@adolor.com
Employees (last reported count): 56
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 57%
·Over the last 6 months:
 · one insider buy; 10.0K shares
 · 16 insider sells; 135.0K shares
  (0.8% of insider shares)
·Institutional: 41% (96% of float)
(90 institutions)
·Net Inst. Buying: 6.71M shares (+34.24%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Adolor Corporation is a therapeutic-based biopharmaceutical company. The Company discovers, develops and plans to commercialize proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by pain treatments. The Company has a portfolio of small-molecule product candidates that are in various stages of development, ranging from preclinical studies to Phase I through Phase II/III clinical trials. The Company's lead product candidate, ADL 8-2698, is designed to selectively block the effects of narcotic analgesics on the gastrointestinal (GI) tract. ADL 8-2698 is a peripherally acting, GI tract-restricted mu opioid receptor antagonist that is designed to block the adverse side effects of narcotic analgesics on the GI tract without blocking their beneficial analgesic effects.
More from Market Guide: Expanded Business Description

Financial Summary
Adolor Corporation is a development-stage pharmaceutical company engaged in the development of peripheral and central analgesics based on opiate receptors and opiate-like receptors. For the six months ended 6/30/01, revenues totaled $562 thousand, up from $18 thousand. Net loss applicable to comm. fell 26% to $16.9 million. Results reflect a $500 thousand milestone payment from an affiliate of GlaxoSmithKline, partially offset by increased salaries and personnel related costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

John Farrar, P.h.D., 56
Pres, CEO, Director
$386K$200K
Peter Schied, 58
CFO, VP, Sec.
220K234K
Andrew Reddick, 48
COO, Sr. VP of Commercial Operations
372K--  
David Jackson, M.D., 54
Sr. VP, R&D
--  --  
Deanne Garver, 42
VP, Preclinical Devel. and Projects Management
203K54K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ADLRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 8-May-2001
$13.36 
Recent Price$18.23 
52-Week High
on 11-June-2001
$29.32 
Daily Volume (3-month avg)231.0K
Daily Volume (10-day avg)122.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y]
26-Week Change+0.9%
26-Week Change
relative to S&P500
+9.9%
Share-Related Items
Market Capitalization$566.9M
Shares Outstanding31.1M
Float13.4M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$5.65 
Earnings (ttm)-$19.25 
Earnings (mrq)-$0.34 
Sales (ttm)$0.03 
Cash (mrq)$5.71 
Valuation Ratios
Price/Book (mrq)3.23 
Price/EarningsN/A 
Price/Sales (ttm)555.77 
Income Statements
Sales (ttm)$588.0K
EBITDA (ttm)-$34.4M
Income available to common (ttm)-$68.3M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-23.64%
Return on Equity (ttm)-70.47%
Financial Strength
Current Ratio (mrq)24.89 
Debt/Equity (mrq)0.00 
Total Cash (mrq)$177.5M
Short Interest
As of 8-Aug-2001
Shares Short351.0K
Percent of Float2.6%
Shares Short
(Prior Month)
530.0K
Short Ratio2.66 
Daily Volume132.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.